VEGFA and glioblastoma: A major clinical placebo-controlled phase III trial investigated the addition of bevacizumab, a monoclonal antibody (mAb) targeting VEGF-A, to the standard treatment regimen of RT and TMZ in patients with newly diagnosed glioblastoma [5].